Pioneering Cancer
Detection with
AI and MRI (and CT)

Bot Image™, Inc. has a flagship product and plans for future applications.

At Bot Image™ AI, we’re on a mission to revolutionize medical imaging through cutting-edge artificial intelligence technology. Our focus is on early detection and precise diagnosis, with our flagship product, ProstatID™, leading the way in the fight against prostate cancer. Explore ProstatID™ or future applications here:

5 Pillars of Prostate AI

Diagnosis / Detection / Screening / Lesion Segmentation / Lesion Classication

All delivered on the foundation of safe bpMRI / Vendor Agnostic / Zero Click/ Seamless Integration

01

Diagnosis

Trained on Thousands of In Bore Biopsy Cases, ProstatID helps Physicians in understanding the severity of the disease state non-invasively.

02

Detection

Prostat ID’s advanced Algorithm is Uniquely Trained in the Detection of Cancerous Tissue.

03

Screening

Prostat ID only requires bpMRI (Non-Contrast) image data to deliver high accuracy results meeting the guidelines for safe and effective screening

04

Lesion Segmentation

Improving departmental workflow, ProstatID precisely segments each lesion with our zero click automation.

05

Lesion Classification

Beyond Segmentation, each lesion is graded using our proprietary indexing value that aligns with the lesions Gleason score. ProstatID provides clinicians with the precision data needed to determine the patients care pathway.

BOT IMAGE, INC

ProstatID is North America’s first FDA-Cleared Prostate Cancer Screening, Detection and Diagnostic AI software.

Explore ProstatID below:

Videos & Photos

Stay informed with our collection of articles, publications, and informative texts detailing the impact of ProstatID™ and the advancements in AI-assisted prostate cancer diagnosis.

Articles & Publications

Stay informed with our collection of articles, publications, and informative texts detailing the impact of ProstatID™ and the advancements in AI-assisted prostate cancer diagnosis.

Our Expertise

Discover the expertise behind Bot Image™, Inc., the team of professionals driving innovation in medical imaging, AI, and healthcare.

How it Works

Explore a simplified explanation of ProstatID™ and its intricate AI algorithms, providing insight into the technology revolutionizing prostate cancer detection.

Discover Our Impact

Learn firsthand about the impact ProstatID™ has had on patients’ lives through testimonials and understand the positive changes our technology is bringing to the world.

Invest in ProstatID

Invest in the future of healthcare by becoming a part of Bot Image™, Inc. Explore investment opportunities and be a driving force in the advancement of medical imaging technology.

OUR FLAGSHIP PRODUCT

How ProstatID Works

Scan

Technologist performs standard screening or diagnostic MRI sequences and pushes the study to their PACs with is Standard Operating Procedure. In parallel, they push the study to the Platform partner of cloud service provider.

Detect

ProstatID automatically detects study, sorts for necessary sequences, checks quality, performs the detection and diagnosis and returns an appended series to the unique patient ID with results and report to view in less than 5 minutes typically = real-time diagnosis.

Diagnose

This new series and report are appended to the study so that the radiologist sees it along with all others on his/her viewing station; hence, no additional effort, equipment or work to perform.

Treat or Don’t Treat

ProstatID assists physicians with treatment planning by providing an entire view of the organ highlighting all suspicious lesions with their individual risk scores. Additionally, if lesion(s) are graded as high risk, they are presented in two powerful 3D views within a transparent rendition of the prostate gland giving interventionalists ideal cognitive targeting.

PAIN POINTS

Why is There a Need for ProstatID and Cancer Detection?

Interpreting & Reading

Interpreting Prostate MRI is very challenging and increases when the patient has other conditions such as BPH (Benign Prostate Hyperplasia), Prostatitis, cysts, etc.

Learn More

Time-consuming

Reading Prostate MRI is time-consuming while searching through stacks of 20-30 slices while simultaneously viewing corresponding slices of multiple series (ie, T2W Axial, DWI, ADC) and cross-checking Coronal and Sagittal Views of T2W.

Learn More

Healthcare and Patient Expense

Prostate MRI can be very expensive and time consuming using contrast agents.

Learn More

The problem with NCCN guidelines

out of date. Historically, the accuracy of radiological interpretation of Prostate MRI has been less than stellar leading to a lack of confidence in the prostate diagnostic space. Loss of confidence in MRI increased resistance to adaptation of it by Urologists

Learn More

Today there is a huge paradigm shift

Bot Image’s Artificial Intelligence greatly improves diagnostic performance of radiologists; provides a wholistic view of the entire prostate improving treatment planning, patient discussions and targeting for interventionalists

Learn More

ProstatID is the Solution!

Easy

ProstatID outputs, physician’s can rely upon the color overlayed T2W image set that indicate segmented lesions with their individual cancer risk score and read through the noise of BPH, benign cysts, prostatitis, etc. This is because of the software was trained to differentiate cancer on over 1000 biopsied cases and with over 6000 biopsy points.

Quick

ProstatID returns the detection and diagnostic results back to the sender typically in less than 5 minutes; hence, the attending physician can begin reading the study while the patient remains on the MRI table; thus, real-time diagnostic assistance.

Rapid Interpretation

Addressed: through clinical studies we have proven that we significantly improve reader performance in early detection of prostate cancer. Our results show that the addition of a boosted parallel random forest model-based CAD generated MRI image series improves inter-reader agreement for PI-RADS classification and the average detection performance for identification of clinically significant prostate cancer among nine readers with varying experience levels in both academic and nonacademic care settings.

PROSTATID

Solution

A clinical study involving 150 prostate MRI studies from assorted MRI systems and field strengths, all with biological (biopsy) ground truth points (pathology verification) was conducted to measure the sensitivity/specificity of the Software, ProstatID using a grid method for 3D location matching. The standalone Performance of ProstatID is shown in the following AUROC curve (sensitivity-specificity).

Bot Image™’s ProstatID as a SaaS medical device AI software

Bot Image™’s ProstatID is also available as a SaaS medical device AI software which requires very little time and effort to connect directly from the hospital or imaging center PACS system to Bot Image™’s Cloud server.   The connection is cyber secure and HIPAA compliant.  Furthermore, Bot Image™ does not process or store PHI – only the Prostate MRI image sets including Axial T2W, DWI and ADC.   Results are returned within a few minutes to the client’s PACS and the output of the software, a post-processed copy of the T2W axial with the colorized overlay indicating suspicious cancer lesions with their margins and risk score annotated on the included PDF report.   NO ADDITIONAL EQUIPMENT, PHYSICIAN EFFORT OR BUTTONS TO PUSH!   Reader simply selects the newly appended series that pops up on the patient MRI viewer and reads the study concurrently with the AI output assistance.

Our Expertise

The Future of Prostate Cancer Diagnosis with AI-Powered MRI

Prostate cancer is one of the most common forms of cancer in men, and early detection is critical to improving

Cracking the Code of Prostate Cancer Staging and Aggressiveness

Understanding how doctors determine the stage and aggressiveness of prostate cancer is crucial for patients and their loved ones. This

Understanding Prostate Cancer Risk Factors to Protect Your Health

Introduction Prostate cancer is a significant health concern for many men worldwide. It is the second most common cancer among

When Should Men Start Screening for Prostate Cancer? Insights for Every Risk Level

Prostate cancer is one of the most common cancers affecting men worldwide. Early detection plays a crucial role in managing

About Bot Image™

Testimonials

“Without a doubt, every urologist dealing with prostate conditions should incorporate ProstatID into their practice. Its indispensable role in improving diagnostic accuracy and guiding therapeutic interventions makes it an indispensable tool in the realm of urology. To forego the utilization of ProstatID would be a disservice to both patients and practitioners alike.”

Testimonial

Dr. Russell Locke, M.D. Vantage Urologic Institute
“We are on board with ProstatID.  I feel more comfortable with this AI backing me up.”
Dr. Woodhouse
“I have come to rely upon the ProstatID output to serve as my own Quality control of interpretation, and it has paid off.”
Anonymous
“I use ProstatID on every case. I first look at all of the colorized suspect lesions, 
then study them and make my diagnosis. Usually, I follow ProstatID 100%. 
ProstatID has been right-on with biopsy confirmation.”
Dr. Lynch Radiologist at Independent Imaging Center
“I’ve known Randy as a friend, a patient-advocate, and, yes-as a nerdy physicist. His ingenuity and eye for the future are only matched by his unflagging support for the health of humanity. This Software gives us a glimpse of how empathy and technology can collide for the good of us all.”
Eric Walser, MD John Sealy Professor and Chairman of Radiology, The University of Texas Medical Branch, Galveston, Texas
“I have the good fortune of knowing Randy (Randall W.) Jones for over twenty years, through our shared interest in optimizing MRI for the care of men with prostate cancer.  Over all these years, Randy has deeply impressed me with his unflagging enthusiasm, innovation, and knowledge.  His passion for advancing medical care continues to drive him forward as he pushes the envelope of imaging technology, building on his unique blend of training, experience, and entrepreneurship.”
Fergus Coakley, MD Professor and Chair, Diagnostic Radiology, OHSU, Portland
“In this wonderful book, Randy Jones articulates a story of success.  It’s a triumph of creativity, science, and entrepreneurship.  This prostate cancer survivor is a nonconformist that responds to challenges with inspiring thought, candor, and conviction.  Through artificial intelligence, Jones has been able to identify lesions in a way the world has yet to see and I’m confident th medical field will endorse.  Ag great educational read from a brave American spirit.”
Dr. Fernando J. Bianco CEO Focalyx
“The problem with most translational science is that you seldom get good feedback between the scientist and the end user.  By being relentless, actively working on both ends of the process without the middlemen, and learning from failures, he has achieved what no one else can.   Physicians are trained to understand a complex system and work within it.   Randy reimagines the system itself.  The Elon Musk of modern MRI development.”
Benjamin B. McDaniel, MD Radiologist, Syracuse, NY

View Investment Opportunities

View Investment Opportunities
slot malaysia